This is a routine insider sale of vested RSU shares. Monitor for any subsequent Form 4 filings to confirm execution, but no material impact is expected.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $14.84entry
- T+1 · 11d ago +3.10%α +2.79% · $15.30
- T+5 · 5d ago +5.12%α +1.83% · $15.60
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Hans van Houte, an officer of Nurix Therapeutics, filed a Form 144 notice of intent to sell 4,769 shares of common stock, with an approximate market value of $123,136 based on the filing date. The shares were acquired via restricted stock units that vested on October 30, 2026. This represents a relatively small portion of the company's $2.8B market cap and is a routine insider sale.
Key Facts
- Hans van Houte, an officer of Nurix Therapeutics, filed Form 144 on 2026-11-04.
- The proposed sale covers 4,769 shares of common stock.
- Estimated aggregate market value of the proposed sale is $123,135.58.
- Shares were acquired via restricted stock units that vested on 2026-10-30.
- The sale is planned to occur on or after 2026-11-04 on Nasdaq.
- The company's market cap is approximately $2.8B, making this sale about 0.004% of market cap.
Financial Impact
Proposed sale of 4,769 shares worth approximately $123,136, representing a small fraction of the officer's holdings and company market cap.
Risk Factors
- Insider sale may signal reduced conviction, though the small size relative to market cap limits concern.
- The sale is not yet executed; the insider may choose not to sell.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010683 |
| Document: 0001950047-26-010683-index.html | 0001950047-26-010683 |
| Document: 0001950047-26-010683.txt | 0001950047-26-010683 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Viewing Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers